Payment overview · 2025
General Payments
$215.12
7 reported records · 4 companies
Healthcare provider profile · identity verified
Sudeep Gupta, DO
Allopathic & Osteopathic Physicians|Family Medicine · DES MOINES, IA · NPI 1114936713
Verified facts
What the public records show
CMS Open Payments records show Sudeep Gupta, DO received $215.12 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 48.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $103.31 | 48.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $79.73 | 37.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.00 | 7.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.08 | 7.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $215.12 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $79.73 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $79.73 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
60 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 347 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 314 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 306 | 101 |
| Omeprazole | Omeprazole | 283 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 261 | 80 |
| Lisinopril | Lisinopril | 221 | 69 |
| Losartan Potassium | Losartan Potassium | 211 | 72 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 183 | 41 |
| Gabapentin | Gabapentin | 166 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 146 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 44 |
| Metformin Hcl Er | Metformin Hcl | 133 | 51 |
| Tramadol Hcl | Tramadol Hcl | 132 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 124 | 26 |
| Ezetimibe | Ezetimibe | 124 | 45 |
| Lorazepam | Lorazepam | 105 | 34 |
| Trazodone Hcl | Trazodone Hcl | 105 | 33 |
| Potassium Chloride | Potassium Chloride | 100 | 29 |
| Bupropion Xl | Bupropion Hcl | 99 | 24 |
| Furosemide | Furosemide | 97 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 24 |
| Montelukast Sodium | Montelukast Sodium | 87 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 45 |
| Meloxicam | Meloxicam | 85 | 27 |
| Ozempic | Semaglutide | 84 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 82 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 27 |
| Jardiance | Empagliflozin | 77 | 16 |
| Sertraline Hcl | Sertraline Hcl | 77 | 26 |
| Metformin Hcl | Metformin Hcl | 76 | 23 |
| Celecoxib | Celecoxib | 75 | 22 |
| Famotidine | Famotidine | 70 | 18 |
| Simvastatin | Simvastatin | 69 | 22 |
| Januvia | Sitagliptin Phosphate | 68 | 15 |
| Mirtazapine | Mirtazapine | 67 | 16 |
| Buspirone Hcl | Buspirone Hcl | 65 | 16 |
| Allopurinol | Allopurinol | 63 | 19 |
| Synthroid | Levothyroxine Sodium | 60 | 18 |
| Mounjaro | Tirzepatide | 55 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 54 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 51 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 49 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | 14 |
| Benazepril Hcl | Benazepril Hcl | 45 | 12 |
| Eliquis | Apixaban | 45 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 45 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 22 |
| Azithromycin | Azithromycin | 44 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 13 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Gemfibrozil | Gemfibrozil | 38 | suppressed |
| Amoxicillin | Amoxicillin | 37 | 24 |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Prednisone | Prednisone | 34 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 32 | 12 |
| Telmisartan | Telmisartan | 32 | 11 |
| Atenolol | Atenolol | 31 | 11 |
| Carvedilol | Carvedilol | 31 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 29 | suppressed |
| Mupirocin | Mupirocin | 28 | 16 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Oxycontin | Oxycodone Hcl | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | 15 |
| Pregabalin | Pregabalin | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 11 |
| Spironolactone | Spironolactone | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 21 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | 20 |
| Tramadol Hcl Er | Tramadol Hcl | 23 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 19 |
| Valacyclovir | Valacyclovir Hcl | 20 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 13 |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Livalo | Pitavastatin Calcium | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $215.12 · 7 records | Novo Nordisk Inc | ELIQUIS, NURTEC ODT, OTEZLA, REPATHA, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error